KLHDC9 (kelch domain containing 9) is a protein-binding molecule with cyclin-binding capacity that functions as a prognostic biomarker in lung adenocarcinoma (LUAD). The protein is characterized by a kelch domain architecture and demonstrates interaction with cell cycle regulatory machinery, including cyclin complexes involved in cell cycle control 1. Mechanistically, KLHDC9 expression is regulated by DNA methylation, which modulates its transcriptional activity in cancer contexts. The gene's altered methylation status and expression levels are associated with LUAD pathogenesis and progression 23. Clinically, KLHDC9 has emerged as a methylation-driven prognostic biomarker for LUAD survival prediction. Combined analysis of KLHDC9 methylation and gene expression independently predicts overall survival outcomes in LUAD patients 23. Furthermore, specific KLHDC9 isoforms correlate with chemotherapy response, particularly to paclitaxel in breast cancer contexts, suggesting its role in drug sensitivity mechanisms 4. These findings establish KLHDC9 as both a potential drug target and a valuable prognostic marker for personalized cancer medicine, though its precise molecular mechanisms in cell cycle regulation and cancer progression require further investigation.